Seaport Therapeutics, Inc. (SPTX) - 10-Q Summary for Q1 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Seaport Therapeutics is a clinical-stage therapeutics company focused on developing oral medicines for neuropsychiatric disorders (depression, anxiety) using its proprietary Glyph platform. The company has no commercial revenue and is currently advancing three primary product candidates: GlyphAllo (for Major Depressive Disorder), GlyphAgo (for Generalized Anxiety Disorder), and Glyph2BLSD (for treatment-resistant depression and PTSD).
Note: The company completed its Initial Public Offering (IPO) in May 2026 (Q2), raising approximately $238.7 million in net proceeds. This filing reflects the pre-IPO capital structure with outstanding convertible preferred stock.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(25,408) | $(13,125) |
| Loss Per Share (Basic & Diluted) | $(10.34) | $(5.65) |
| Operating Expenses | $27,543 | $16,185 |
| Cash, Cash Equivalents & Investments | $212,645 | $215,983 |
| Accumulated Deficit | $(139,517) | $(52,353) |
| Net Cash Used in Operating Activities | $(20,172) | $(20,205) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $12.3 million (94%) year-over-year, driven primarily by a $10.9 million increase in Research and Development (R&D) expenses.
- R&D Expense Growth: R&D expenses rose from $10.5 million to $21.4 million. This was due to the advancement of the Phase 2b BUOY-1 trial for GlyphAllo and the Phase 1 trial for GlyphAgo.
- Investment Portfolio Shift: While total cash and investments remained relatively stable, the company saw a net cash inflow of $27.9 million from investing activities in Q1 2026 (vs. outflow of $225.6 million in Q1 2025) due to proceeds from maturities of investments exceeding new purchases.
- Stock-Based Compensation: Total stock-based compensation increased to $2.6 million from $1.6 million, reflecting additional equity grants.
Guidance, Outlook, and Risks
- Clinical Milestones:
- GlyphAllo: Phase 2b BUOY-1 trial (MDD) is ongoing; topline data expected in H1 2027. A Phase 1 driving simulation trial is underway with data expected in H2 2026.
- GlyphAgo: Phase 1 SAD and crossover data showed a 6.8-fold increase in bioavailability. Phase 1 MAD data (June 2026) showed therapeutic exposures without liver-related adverse events. Phase 2a/2b trials planned for 2028.
- Liquidity and Runway: As of March 31, 2026, the company held $212.6 million in cash and investments. Management believes this, combined with the Q2 2026 IPO proceeds, is sufficient to fund operations into 2029.
- Key Risks:
- Development Risk: No products are approved; success depends on clinical trial outcomes and regulatory approval.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and may require additional financing.
- Third-Party Reliance: Reliance on CROs for clinical trials and CMOs for manufacturing.
- Intellectual Property: Heavy reliance on in-licensed IP from Monash University and PureTech.
Investor Verification Checklist
- Verify the timing and enrollment rates of the Phase 2b BUOY-1 trial for GlyphAllo, as this is the primary near-term catalyst.
- Confirm the liver safety profile of GlyphAgo in upcoming Phase 2 trials, given the historical liver toxicity concerns with agomelatine.
- Monitor the burn rate relative to the $212.6 million cash balance to validate the 2029 runway estimate post-IPO.
- Review the terms of the Monash University License Agreement for potential milestone payment obligations upon regulatory or commercial success.
- Assess the impact of the reverse stock split (1-for-3.1407) executed in April 2026 on share count and liquidity.